Keith-Harrison by changcheng2


									                      Keith J. Harrison

                                                         Practice Areas
              Keith J. Harrison                           Health Care
              Partner                                     Labor & Employment
                                                          Trial Practice
                           Intellectual Property
                                                          Antitrust
              Washington                                  Health Care Litigation
              1001 Pennsylvania Avenue, N.W.              Health Care Fraud &
              Washington, DC 20004-2595                    Abuse
              Phone: 202.624.2560                         Labor &
              Fax: 202.628.5116                            Employment/ERISA

Keith J. Harrison is a partner in the firm's Washington, D.C. office, and
leader of the Crowell & Moring Trial Practice Team. Having succesfully tried
more than 45 jury trials to verdict, Keith uses his extensive trial experience to
develop winning strategies for his clients. Keith's litigation practice focuses on
biotech, pharmaceutical, and Life Sciences litigation. In 2007 and 2008, he
was selected as a Washington, D.C. "Super Lawyer" in the field of intellectual
property litigation by Super Lawyers. Keith is also a member of the firm's
Diversity Council.

Keith has won jury verdicts in numerous patent, trade secret, breach of
contract, employment defense and white collar criminal trials. He also has a
record of winning cases at the pretrial stage in a wide range of cases
involving patents, bioinformatic license arrangements, antitrust and unfair
competition claims, class actions against managed care plans, trade secrets,
FDA consent decrees, government healthcare contract disputes, biotech
licensing disputes, Medicaid procurement, and the Federal Employees Health
Benefits Program. As a former prosecutor, Keith has decades of experience in
conducting confidential internal investigations that have ranged from major
League Baseball's investigation of Pete Rose to the United Nations Iraq Oil for
Food Program. Keith also represents individuals and companies testifying
before Congress.

Keith served as lead trial counsel in MorphoSys v. Cambridge Antibody
Technology, where he successfully tried a three-week biotech patent
infringement jury trial about phage display antibody library technology.
Recently, Keith was lead trial counsel in Celera Genomics v. Wyeth, Inc., a
jury trial concerning Celera Genomic's historic decoding of the human genome
and the licensing of its genetic database, which settled after Keith's opening
statement. Another of Keith's reported intellectual property cases is Ellis v.
Hurson, the leading case in the District of Columbia on trade secrets and
noncompetition agreements. In addition, Keith successfully represented jWIN
Electronics in patent infringement litigation regarding V-Chips or parental

                             Page 1 of 3
                     Keith J. Harrison

control technology in DVD players in the Eastern District of Texas. Keith's
biotech, pharmaceutical and technology clients include Cambridge Antibody
Technology, Compugen, Celera Genomics, Caraco Pharmaceutical
Laboratories, and Innovassynth Technologies.

Keith also serves as litigation counsel to one of the Washington metropolitan
area's largest healthcare companies, MedStar Health, Inc. and its subsidiary
hospitals, including Washington Hospital Center, Georgetown University
Hospital, National Rehabilitation Hospital and Good Samaritan Hospital. Other
businesses that look to Keith for representation include Kaiser Foundation
Health Plan of the Mid-Atlantic States.

Keith is a past member of the Board of Governors for The Federal Circuit Bar
Association. He is also a member of the American Bar Association ("ABA")
Sections of Litigation and Intellectual Property Law. Keith is admitted to the
District of Columbia and New York Bars. He is also admitted to practice before
the United States District Court for the District of Columbia; Eastern District
of Michigan, the United States Courts of Appeals for the Federal, District of
Columbia, Fifth, Sixth and Eleventh Circuits; as well as the United States
Court of Federal Claims.

Keith is a contributor, author and co-author of several articles on the
procedural and substantive aspects of biopharma litigation, healthcare law,
litigation, internal investigations and intellectual property matters. He has
also lectured on these topics and was most recently featured as a faculty
member on the ABA's closed circuit television seminar programs. Keith is a
faculty member of the National Institute for Trial Advocacy where he trains
lawyers in the art of trial advocacy.

After law school, Keith served as an Assistant District Attorney for the County
of New York (Manhattan), where he prosecuted over 200 felony cases,
including homicide, assault, rape, robbery, arson, embezzlement,
counterfeiting and grand larceny. As an Assistant District Attorney, Keith was
lead counsel in numerous jury trials, each returning a verdict in his favor. In
1988, he entered private practice in Washington, D.C.


     College of William and Mary, B.A. (1981)
     University of Virginia School of Law, J.D. (1984)

                            Page 2 of 3
                     Keith J. Harrison


Admitted to practice: District of Columbia, New York


     "A Comparative Analysis of the United States Biosimilar Pathway,"
      American Health Lawyers Association (July 2010). Author: Keith J.
     "International Arbitration In The Middle East: A Case Study of Qatar,"
      The International Dispute Resolution News, Vol. 1, No. 1 (Fall 2009).
      Authors: Meriam N. Alrashid, Keith J. Harrison, Brian E. Abrams and
      Jonas B. Lerman.

Alerts & Newsletters

     "Finally—A Regulatory Pathway for Biosimilars in the United States,"
      Life Sciences Alert (March 26, 2010). Contacts: Keith J. Harrison, Kristof
     "Pharmaceutical and Medical Device Industries are The Top Targets for
      Foreign Corrupt Practices Act ("FCPA") Enforcement," Life Sciences Alert
      (November 18, 2009). Contacts: Keith J. Harrison, Stephen M. Byers,
      Alan W. H. Gourley.
     "The Generic Biologics Debate Heats Up With Introduction of Rival
      House Bill," Life Sciences Alert (March 24, 2009). Contact: Keith J.
     "House Introduces Legislation On Generic Biologics Approval Process,"
      Life Sciences Alert (March 12, 2009). Contact: Keith J. Harrison.
     "The Obama Administration Stakes Out Positions on Generic Biologics,
      Hatch-Waxman Settlements and Evergreening in Its First Budget," Life
      Sciences Alert (March 4, 2009). Contact: Keith J. Harrison.
     "Federal Circuit Affirms Extension of The 30 Month Hatch-Waxman Stay
      Preventing FDA Approval of Generic Version of Evista," IP Insights
      (February 27, 2009). Contacts: Keith J. Harrison, Mark Supko.

Speaking Engagements

     "U.S. Healthcare Reform: What's in it for Biosimilars?" European
      Generics Medicines Association's 8th Annual Symposium on Biosimilars,
      London (September 8-10, 2010). Presenter: Keith J. Harrison.
     "Mapping Out The Latest Developments in European And US Biosimilar
      Regulation-Achieving Cost Effective Compliance," Biosimilars India 2009
      Conference (December 2, 2009). Presenter: Keith J. Harrison.

                           Page 3 of 3

To top